US Patent Issued to ANBOGEN THERAPEUTICS on March 4 for "Crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-dpyrimidin-5-yl)phenyl)but-2- enamide free base" (Taiwanese Inventors)

ALEXANDRIA, Va., March 5 -- United States Patent no. 12,240,858, issued on March 4, was assigned to ANBOGEN THERAPEUTICS INC (Taipei, Taiwan).

"Crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-dpyrimidin-5-yl)phenyl)but-2- enamide free base" was invented by Tsu-An Hsu (Taipei, Taiwan), Hsing-Pang Hsieh (Taipei, Taiwan) and Sue-Ming Chang (Taipei, Taiwan).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein is a specific crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide (ABT-101) free base, the pharmaceutical composition and capsule comprising the same, and t...